Similar articles

• Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study.

  Provenzano G, Termini A, Le Moli C, Rinaldi F. Provenzano G, et al. Ann Rheum Dis. 2003 Jul;62(7):680-1. doi: 10.1136/ard.62.7.680. Ann Rheum Dis. 2003. PMID: 12810436 Free PMC article. No abstract available.
• Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.

  Gratacós J, Casado E, Real J, Torre-Alonso JC. Gratacós J, et al. Ann Rheum Dis. 2007 Apr;66(4):493-7. doi: 10.1136/ard.2006.060079. Epub 2006 Dec 19. Ann Rheum Dis. 2007. PMID: 17179176 Free PMC article. Clinical Trial.
• Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.

  Covelli M, Scioscia C, Iannone F, Lapadula G. Covelli M, et al. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):145-51. Clin Exp Rheumatol. 2005. PMID: 15895882 Clinical Trial.
• Psoriatic arthritis.

  Durham LE, Taams LS, Kirkham BW. Durham LE, et al. Br J Hosp Med (Lond). 2016 Jul;77(7):C102-8. doi: 10.12968/hmed.2016.77.7.C102. Br J Hosp Med (Lond). 2016. PMID: 27388392 Review. No abstract available.
• Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.

  Mease PJ. Mease PJ. Ann Rheum Dis. 2002 Apr;61(4):298-304. doi: 10.1136/ard.61.4.298. Ann Rheum Dis. 2002. PMID: 11874829 Free PMC article. Review.